Daily Anesthesiology Research Analysis
Analyzed 41 papers and selected 3 impactful papers.
Summary
Analyzed 41 papers and selected 3 impactful articles.
Selected Articles
1. Volatile anaesthetics modulate voltage-gated sodium channel function at a site directly linked to channel gating.
The study identifies an atomic-resolution sevoflurane binding pocket in VGSCs that displaces lipid to modulate channel inactivation, with mutational abrogation of both binding and inactivation shifts. Functional effects extend to human Nav1.1, including modulation of steady-state slow inactivation, supporting a conserved anesthetic interaction site across VGSCs.
Impact: Defines a concrete, conserved binding site linking volatile anesthetic-lipid interactions to VGSC gating, advancing molecular understanding of general anesthesia and informing rational anesthetic design.
Clinical Implications: While preclinical, these findings suggest VGSCs as actionable targets for tailoring anesthetic profiles (e.g., effects on excitability, seizure threshold), and may guide development of agents minimizing neurotoxicity while preserving desired hypnosis/immobility.
Key Findings
- X-ray crystallography revealed a sevoflurane binding pocket in NavMs that displaces membrane lipid in a hydrophobic cavity.
- Mutating an invariant tyrosine in the pocket abolished sevoflurane binding and its hyperpolarizing shift of steady-state inactivation.
- Sevoflurane modulated both fast and slow inactivation in human Nav1.1, demonstrating VA control of steady-state slow inactivation.
- Evidence indicates homologous VA interaction sites across prokaryotic and human VGSCs.
Methodological Strengths
- Atomic-resolution structural determination of ligand binding with X-ray crystallography.
- Cross-system functional validation (NavMs, NaChBac, human Nav1.1) coupled with targeted mutagenesis.
Limitations
- Structural work centers on prokaryotic channels; direct in vivo human validation is lacking.
- No behavioral or systems-level anesthetic endpoints to link to clinical outcomes.
Future Directions: Map homologous binding sites across human VGSC isoforms in situ, and exploit structure-guided design to engineer anesthetics with selective channel subtype modulation and improved safety.
Voltage-gated sodium channels (VGSCs) mediate neuronal excitability and synaptic transmission and are functionally relevant targets for volatile anaesthetic (VA) actions. Here, we show that multiple VAs at clinically relevant concentrations share binding sites on NavMs, a prokaryotic VGSC. Sevoflurane, a representative VA, interacts with NavMs and NaChBac with functional effects paralleling those on human VGSCs, including modulation of channel inactivation. X-ray crystallography of purified NavMs reveals an atomic-resolution VA binding site in a VGSC, in which sevoflurane displaces lipid to occupy a membrane-embedded hydrophobic pocket. Alanine substitution of an invariant tyrosine within this binding pocket abolishes sevoflurane binding and eliminates the sevoflurane-induced hyperpolarising shift of steady-state inactivation. Sevoflurane modulates both fast and slow inactivation of human Nav1.1, demonstrating VA modulation of steady-state slow inactivation in a neuronal VGSC. Supporting evidence shows that VAs interact with homologous sites in human VGSCs. These findings define a VA binding site in VGSCs that supports a membrane-assisted pathway for modulating channel gating and neuronal activity in general anaesthesia.
2. Implementation of the kidney protection strategy in critically ill patients with acute kidney injury - a multi-center prospective cohort study.
In a multicenter prospective cohort of 258 ICU patients with KDIGO stage 2–3 AKI, complete KDIGO kidney protection strategy adherence occurred in 31% and was strongly associated with improved renal recovery at discharge and reduced 30-day RRT, with a dose–response across bundle components. MAP optimization had the lowest implementation rate.
Impact: Demonstrates real-world underuse of a guideline-recommended kidney protection bundle and links adherence to clinically meaningful renal outcomes, providing an actionable quality-improvement target in critical care.
Clinical Implications: Adopt standardized KPS checklists and monitoring (especially MAP >65 mmHg) within 12 hours of AKI diagnosis; track adherence to components to drive renal recovery and reduce need for RRT.
Key Findings
- Only 31% achieved complete KPS implementation; MAP optimization had the lowest uptake (33%).
- KPS adherence associated with higher renal recovery at discharge (SHR 6.02; adjusted SHR 6.29) and lower 30-day RRT (SHR 0.12).
- Dose–response relationship between number of KPS components implemented and better renal outcomes; reduced AKD beyond day 7 (SHR 0.64).
Methodological Strengths
- Prospective multicenter design with standardized definitions and competing risk analyses.
- Multivariable adjustment and demonstration of dose–response across bundle components.
Limitations
- Observational design limits causal inference; adherence may be confounded by illness severity and resource availability.
- Conducted in European ICUs; generalizability to other settings may vary.
Future Directions: Test KPS bundle implementation strategies in pragmatic trials (e.g., stepped-wedge designs), focusing on MAP optimization and nephrotoxin avoidance, and evaluate patient-centered outcomes and cost-effectiveness.
BACKGROUND: The international Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend the implementation of a kidney protection strategy (KPS) in patients at high risk of and with Acute Kidney Injury (AKI). However, real-world implementation of this strategy in critically ill patients with AKI is unclear. We quantified timely and sustained adherence to KPS in critically ill adults with moderate-to-severe (KDIGO stage 2 or 3) AKI and explored associations with clinical outcomes. METHODS: This was a multicenter, prospective cohort study enrolling adult patients with moderate or severe AKI requiring vasopressors and/or mechanical ventilation across five centers in Europe. The primary endpoint was adherence to the KPS, which included hemodynamic monitoring, sustained optimization of mean arterial pressure (MAP) > 65 mmHg, monitoring of serum creatinine and urine output, and avoidance of hyperglycemia, radiocontrast agents and nephrotoxins when possible, within 12 h after AKI diagnosis for 48 h or until ICU discharge. Exploratory analyses examined associations between adherence and renal outcomes. RESULTS: A total of 258 patients were enrolled (median age 69 years [IQR 62-75]; 65% male; median SOFA 10 [IQR 8-13]). The complete KPS was implemented in 80 patients (31%; 95% CI, 25.5-37.2%). Adherence to individual components of the KPS varied widely with optimization of MAP showing the lowest implementation rate (33%). In exploratory analyses accounting for death as a competing risk, KPS adherence was associated with a lower incidence of AKD beyond day 7 (subdistribution hazard ratio [SHR] 0.64; 95% CI, 0.41-0.99; p = 0.046), a higher incidence of renal recovery at hospital discharge (SHR 6.02; 95% CI, 4.00-9.05; p < 0.0001), and a lower incidence of RRT within 30 days (SHR 0.12; 95% CI, 0.02-0.91; p = 0.04). After multivariable adjustment, the association with renal recovery remained robust (adjusted SHR 6.29; 95% CI, 3.08-12.85; p < 0.0001). A clear dose-response relationship was observed between the number of implemented KPS components and renal outcomes. CONCLUSIONS: In critically ill patients with moderate-to-severe AKI, the complete KDIGO-recommended kidney protection strategy was implemented in approximately one-third of patients, and full KPS adherence was associated with a higher rate of renal recovery at hospital discharge.
3. Environmental enrichment mitigates sevoflurane-induced neurodevelopmental injury via cGAS-STING-dependent microglial modulation.
Neonatal sevoflurane triggers mitochondrial dysfunction and mtDNA-driven cGAS–STING activation in microglia, leading to excessive synaptic pruning and cognitive deficits. Environmental enrichment preserves mitochondrial integrity, dampens cGAS–STING signaling, normalizes microglial pruning, and improves cognition; impoverished environments worsen injury.
Impact: Links a defined innate immune pathway (cGAS–STING) and microglial pruning to anesthesia-related neurodevelopmental injury, and identifies modifiable environmental and pharmacologic targets.
Clinical Implications: Although preclinical, results support evaluating perioperative strategies that reduce mitochondrial injury and cGAS–STING activation (e.g., neuroprotective environments, pathway inhibitors) in infants at risk of anesthesia-related developmental effects.
Key Findings
- Sevoflurane caused cognitive impairment, microglial overactivation, mitochondrial dysfunction, and excessive synaptic pruning in neonatal mice.
- Environmental enrichment preserved mitochondrial integrity, reduced mtDNA-driven cGAS–STING activation, normalized microglial pruning, and improved cognition.
- Impoverished environment exacerbated mitochondrial injury, synaptic loss, and cognitive deficits; pharmacologic inhibition was used to probe pathway involvement.
Methodological Strengths
- Multi-level assessment (behavioral, cellular, mitochondrial, and innate immune signaling) with environmental and pharmacologic manipulations.
- Convergent evidence linking mtDNA, cGAS–STING activation, microglial pruning, and cognition.
Limitations
- Mouse neonatal model may not fully recapitulate human infant anesthetic exposure and long-term outcomes.
- Specificity of cGAS–STING effects to sevoflurane versus other anesthetics remains to be defined.
Future Directions: Translate to large-animal and clinical studies assessing perioperative environmental modulation and cGAS–STING-targeted interventions, with long-term neurodevelopmental follow-up.
BACKGROUND: Neonatal exposure to sevoflurane has been implicated in long-term neurodevelopmental abnormalities, yet the underlying mechanisms remain unresolved. This study sought to determine whether cGAS-STING-mediated microglial activation and aberrant synaptic pruning underlie sevoflurane-induced cognitive deficits and to assess how environmental conditions modulate these processes. METHODS: Neonatal mice underwent sevoflurane exposure followed by rearing in enriched (EE) or impoverished (IE) environments. Cognitive function, synaptic structure, microglial activity, mitochondrial status, and cGAS-STING signaling were evaluated using behavioral tests, immunostaining, biochemical assays, and pharmacological inhibition. RESULTS: Sevoflurane exposure induced cognitive impairment, microglial overactivation, mitochondrial dysfunction, and excessive synaptic pruning resulting from microglial overactivation. EE mitigated these abnormalities by preserving mitochondrial integrity and reducing mtDNA-driven cGAS-STING activation, thereby preventing the microglia-mediated imbalance in synaptic pruning and improving cognitive outcomes. In contrast, IE exacerbated mitochondrial injury, aggravated synaptic loss, and further worsened cognitive impairment. CONCLUSION: Sevoflurane disrupts neurodevelopment through a mitochondria-cGAS-microglia-synapse pathway. Environmental enrichment offers significant neuroprotection, highlighting both cGAS-STING signaling and early-life environmental modulation as promising targets for preventing anesthesia-related neurodevelopmental injury.